• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center


    New Core: Recombinant Protein Expression and Purification

    The Recombinant Protein Expression and Purification (RPrEP) Core was launched in 2009 to provide a cost-effective resource to the DF/HCC community for expression and purification of recombinant fusion proteins necessary for pre-clinical studies as well as for basic mechanistic studies by immunologists and cancer biologists

    Tissue Microarray and Imaging Core

    The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research

    Community Practice Core

    The Community Practice Core (CPC) offers access to a clinical laboratory of over ten million patients within Harvard Vanguard Medical Associates, Harvard Pilgrim Health Care, and the HMO Cancer Research Network

    Twelve new members join DF/HCC

    Twelve individuals have recently joined DF/HCC

    Bortezomib denies leukemia stem cell development

    Acute myelogenous leukemia (AML), a disease for which treatment has remained relatively unchanged for the past 30 years, is the subject of a new clinical trial featuring a drug aimed at boosting the efficacy of standard induction chemotherapy

    Delivering a one-two punch to the PI3K signaling pathway

    Based largely on original research from a team of DF/HCC investigators, a new clinical trial has launched to determine if combination therapy with a tyrosine kinase inhibitor (neratinib) in combination with an mTOR inhibitor (temsirolimus, Torisel®) can more effectively shut down an important signaling pathway involved in solid tumors like lung and breast cancers

    Co-clinical mouse/human trials aim to speed up drug approvals

    The many breakthroughs in understanding the pathways involved in leukemia have delivered a double-edged sword: hundreds of new drugs await testing but an insufficient patient pool exists to conduct clinical testing in a timely way

Displaying results 106 to 112 out of 229